Back to search

Article

Diagnostic performance of serum mac-2-binding protein glycosylation isomer as a fibrosis biomarker in non-obese and obese patients with MASLD

2024-12-25

Abstract excerpt

<title>Abstract</title> <p>Aim Serum mac-2-binding protein glycosylation isomer (M2BPGi) is a new biomarker for liver fibrosis. However, its performance in metabolic dysfunction-associated steatotic liver disease (MASLD), particularly in obese patients, remains to be explored. Methods This study evaluated the role of M2BPGi in predicting liver fibrosis in 205 patients with MASLD using magnetic resonance elastog...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2456f1a9-cfe0-5c25-9ee2-01696d9f63b5
DOI
10.21203/rs.3.rs-5473146/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Diagnostic performance of serum mac-2-binding protein glycosylation isomer as a fibrosis biomarker in non-obese and obese patients with MASLDDOI 10.21203/rs.3.rs-5473146/v1
Clinical implications of serum Mac-2-binding protein (M2BPGi) as novel biomarkers of advanced hepatic fibrosis in diabetesSemantic proximity
Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert reviewSemantic proximity
FIB-4 First in Diagnostic Algorithm of MAFLD at the Era of “Global Metabodemic “Semantic proximity
Elevated Serum Growth Differentiation Factor 15 and Decorin Predict the Fibrotic Progression of Metabolic Dysfunction Associated Steatotic Liver DiseaseSemantic proximity
Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity
Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver BiomarkersSemantic proximity
Non-Invasive Evaluation of MAFLD and the Contribution of Genes: An MRI-PDFF-Based Cross-Sectional StudySemantic proximity
High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver diseaseSemantic proximity
Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease.Semantic proximity
Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with Metabolically Dysfunction Associated Steatotic Liver DiseaseSemantic proximity
A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitisSemantic proximity
Metabolic and Clinical Heterogeneity in MASLD Risk Stratification: Independent Effects of Body Mass Index and Fib-4 on Cirrhosis, and Clinical Implications of Noninvasive Score Discordance in a Veteran CohortSemantic proximity
Select a neighboring publication to make it the new centre.